DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Change of Personnel Eckert & Ziegler: New Executive Board member for Radiation Therapy. Harald Hasselmann succeeds Edgar Löffler. 23.12.2016 / 17:40 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Berlin, December 23, 2016 - The Supervisory Board of Eckert & Ziegler AG has appointed Dr. Harald Hasselman (49) as the new Executive Board member for the Radiation Therapy segment with effect from January 1, 2017. He succeeds Dr. Edgar Löffler (63), who will retire from the company as planned at the end of 2016, thereby stepping down from his duties. Dr. Löffler will continue to be available to the company under a consulting agreement. "Since 2001, Dr. Löffler has played an instrumental role in the development of our Therapy segment and in establishing Eckert & Ziegler as a major, globally active provider of cancer radiation systems," company founder and Chairman of the Executive Board Dr. Andreas Eckert said. "Our success as the European market leader in prostate implants would have been inconceivable without him. The Executive and Supervisory Boards would like to thank Edgar Löffler for these achievements and look forward to continuing to have him at their side." Dr. Hasselmann has worked for the Eckert & Ziegler Group since 2015. As the Commercial Managing Director of Eckert & Ziegler BEBIG GmbH, he has successfully implemented the realignment of the specialist for brachytherapy. Hasselmann, a native of Hamburg, has many years of experience at international pharmaceutical companies. His positions include head of controlling for Europe at Bayer Pharma, managing director at Schering's Hungarian subsidiary, and director of the Berlin-based biotech company metaGen. He has held various positions at large and medium-sized healthcare companies and has a proven track record in sales, controlling, and implementing restructuring measures. About Eckert & Ziegler. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with approximately 670 employees, is one the world's largest providers of isotope technology for radiation therapy and nuclear medicine. Contributing to saving lives. Your contact: Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, 13125 Berlin, Germany Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.de --------------------------------------------------------------------------- 23.12.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Eckert & Ziegler Strahlenund Medizintechnik AG Robert-Rössle-Str.10 13125 Berlin Germany Phone: 49 30 941084-138 Fax: 49 30 941084-112 E-mail: [email protected] Internet: www.ezag.de ISIN: DE0005659700 WKN: 565970 Listed: Regulated Market in Frankfurt (Prime Standard), Stuttgart; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 532923 23.12.2016